Our management's discussion and analysis of financial condition and results of operations reflects the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. We believe our investments in the industry's largest sales organization, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our R&D efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so they remain relevant for our customers. The animal health medicines and vaccines industry is characterized by meaningful differences in customer needs across different regions, which necessitates a focus on operational flexibility and the ability to tailor our offerings in response to changing business needs and directions. Our management team's focus on improving operational and cost efficiencies increases the likelihood of achieving our core growth strategies and enhancing long-term value for our shareholders. The overall economic environment, along with industry-specific factors, poses challenges related to global economic conditions that could impact our liquidity and ability to meet future financing needs. We face competition in the regions in which we operate, and our principal methods of competition include new product development, quality, price, service, and promotion to veterinary professionals, pet owners, and livestock producers. Our competitors include the animal health businesses of large pharmaceutical companies and specialty animal health businesses. We also compete with companies that produce generic products, particularly in markets where the level of generic competition is higher. The importance of quality and safety concerns to pet owners, veterinarians, and livestock producers contributes to brand loyalty, which we believe often continues after the loss of patent-based and regulatory exclusivity. We depend on positive perceptions of the safety and quality of our products, and we recognize that the transfer of increased antibacterial resistance in bacteria from food-producing animals to human pathogens is a subject of global scientific and regulatory discussion. Our future success depends on both our existing product portfolio and our pipeline of new products, including those developed through joint ventures and acquisitions. Our strategic resource allocation and investment decisions are critical in maintaining our competitive advantage and ensuring that we can respond effectively to market dynamics. We believe that our manufacturing and supply chain capabilities provide us with a global platform for continued expansion, including in emerging markets, and that our quality and reliability differentiate us from our competitors. The challenges associated with regulatory compliance and the need for operational efficiency underscore the necessity for effective IT governance and management practices to support our organizational goals and enhance our overall performance.